• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Design, synthesis and biological evaluation of novel oseltamivir derivatives as potent neuraminidase inhibitors

tetano

Editor, Senior Moderator
Bioorg Med Chem Lett. 2017 Nov 4. pii: S0960-894X(17)31079-X. doi: 10.1016/j.bmcl.2017.11.003. [Epub ahead of print]
[h=1]Design, synthesis and biological evaluation of novel oseltamivir derivatives as potent neuraminidase inhibitors.[/h] Wang Z[SUP]1[/SUP], Cheng LP[SUP]2[/SUP], Zhang XH[SUP]1[/SUP], Pang W[SUP]1[/SUP], Li L[SUP]1[/SUP], Zhao JL[SUP]1[/SUP].
[h=3]Author information[/h]

[h=3]Abstract[/h] Neuraminidase (NA) is one of the particular potential targets for novel antiviral therapy. In this work, a series of neuraminidase inhibitors with the cyclohexene scaffold were studied based upon the combination of 3D-QSAR, molecular docking, and molecular dynamics techniques. The results indicate that the built 3D-QSAR models yield reliable statistical information: the correlation coefficient (r[SUP]2[/SUP]) and cross-validation coefficient (q[SUP]2[/SUP]) of CoMFA (comparative molecular field analysis) are 0.992 and 0.819; the r[SUP]2[/SUP] and q[SUP]2[/SUP] of CoMSIA (comparative molecular similarity analysis) are 0.992 and 0.863, respectively. Molecular docking and MD simulations were conducted to confirm the detailed binding mode of enzyme-inhibitor system. The new NA inhibitors had been designed, synthesized, and their inhibitory activities against group-1 neuraminidase were determined. One agent displayed excellent neuraminidase inhibition, with IC[SUB]50[/SUB] value of 39.6 μM against NA, while IC[SUB]50[/SUB] value for oseltamivir is 61.1 μM. This compound may be further investigated for the treatment of infection by the new type influenza virus.
Copyright ? 2017. Published by Elsevier Ltd.


[h=4]KEYWORDS:[/h] 3D-QSAR; Molecular docking; Molecular dynamics simulations; Neuraminidase inhibitors; Oseltamivir derivatives

PMID: 29141777 DOI: 10.1016/j.bmcl.2017.11.003
 
Back
Top Bottom